4 documents found, page 1 of 1
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE) : a...
van Maurik, Ingrid S; Vos, Stephanie J.; Bos, Isabelle; Bouwman, Femke H; Teunissen, Charlotte E.; Scheltens, Philip; Barkhof, Frederik; Frolich, LutzBackground: Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. Methods: In this modelling study, we included people with mild cognitive impairment (MCI) fro...
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a ...
van Maurik, Ingrid S.; Vos, Stephanie J.; Bos, Isabelle; Bouwman, Femke H.; Teunissen, Charlotte E.; Scheitens, Philip; Barkhof, Frederik; Frolich, LutzBackground Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. Methods In this modelling study, we included people with mild cognitive impairment (MCI) from ...
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairmen...
Vos, Stephanie J. B.; Verhey, Frans; Frölich, Lutz; Kornhuber, Johannes; Wiltfang, Jens; Maier, Wolfgang; Peters, Oliver; Rüther, Eckart; Nobili, FlavioThree sets of research criteria are available for diagnosis of Alzheimer's disease in subjects with mild cognitive impairment: the International Working Group-1, International Working Group-2, and National Institute of Aging-Alzheimer Association criteria. We compared the prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage according to these criteria. Subjects with mild cognit...
Biomarkers for Alzheimer's disease therapeutic trials
Hampel, Harald; Wilcock, Gordon; Andrieu, Sandrine; Aisen, Paul; Blennow, Kaj; Broich, K.; Carrillo, Maria; Nick, C. Fox; Frisoni, Giovanni B.The development of disease-modifying treatments for Alzheimer's disease requires innovative trials with large numbers of subjects and long observation periods. The use of blood, cerebrospinal fluid or neuroimaging biomarkers is critical for the demonstration of disease-modifying therapy effects on the brain. Suitable biomarkers are those which reflect the progression of AD related molecular mechanisms and neuro...